Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Glenmark's current portfolio consists of 197 products authorized for distribution in the U.S. marketplace
New software solution helps manufacturers digitalize and gain insights from data to increase efficiency
New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH
HaystackAnalytics is engaged in the business of developing genomic analysis software
Oligonucleotides are a unique modality with potential to address hard-to-treat diseases with high unmet need
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
PICCOLO trial met its primary endpoint of objective response rate (ORR)
The special Tele MANAS cell to serve as a dedicated mental health assistance helpline for all Armed Forces beneficiaries across country
Subscribe To Our Newsletter & Stay Updated
